Earnings per share of $0.47 expected for Endo International plc (NASDAQ:ENDP) this quarter

0

Equity research analysts expect Endo International plc (NASDAQ:ENDP – Get Rating) (TSE:ENL) to report earnings per share (EPS) of $0.47 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have released earnings estimates for Endo International. The lowest EPS estimate is $0.43 and the highest is $0.50. Endo International reported earnings per share of $0.65 in the same quarter last year, indicating a negative 27.7% year-over-year growth rate. The company is due to release its next quarterly results on Monday, January 1.

On average, analysts expect Endo International to report annual earnings of $1.70 per share for the current fiscal year, with EPS estimates ranging from $1.49 to $1.95. For the next fiscal year, analysts expect the company to post earnings of $1.12 per share, with EPS estimates ranging from $0.78 to $1.38. Zacks Investment Research earnings per share averages are an average average based on a survey of research analysts who provide coverage for Endo International.

Endo International (NASDAQ:ENDP – Get Rating) (TSE:ENL) last released its results on Thursday, May 5. The company reported EPS of $0.66 for the quarter, beating the consensus estimate of $0.44 by $0.22. Endo International had a negative return on equity of 90.96% and a negative net margin of 20.49%. The company posted revenue of $652.26 million in the quarter, compared to $637.09 million expected by analysts. In the same period a year earlier, the company had earned earnings per share of $0.73. The company’s revenue was down 9.1% year over year.

Several equity research analysts have published reports on ENDP shares. Piper Sandler downgraded shares of Endo International from a “neutral” rating to an “underweight” rating and lowered her target price for the company from $3.00 to $1.00 in a research report on Friday . StockNews.com began covering Endo International in a research note on Thursday, March 31. They issued a “holding” rating on the stock. Citigroup lowered its price target on Endo International from $11.00 to $6.00 and set a “buy” rating for the company in a Wednesday, March 9 research note. TheStreet upgraded Endo International from a “c-” rating to a “d” rating in a Wednesday, February 2 report. Finally, Barclays downgraded Endo International from an “equal weight” rating to an “underweight” rating and reduced its target price for the stock from $5.00 to $2.00 in a research note. Wednesday, March 2. Three investment analysts gave the stock a sell rating, two gave the company a hold rating and two gave the company a buy rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.50.

Shares of NASDAQ ENDP opened at $1.42 on Friday. The company has a 50-day moving average of $2.33 and a 200-day moving average of $3.61. The company has a market capitalization of $331.81 million, a price-earnings ratio of -0.46 and a beta of 1.07. Endo International has a 12-month low of $1.28 and a 12-month high of $7.07.

A number of institutional investors have recently changed their positions in ENDP. NorthCrest Asset Management LLC purchased a new stake in Endo International in the first quarter worth approximately $28,000. Vantage Consulting Group Inc purchased a new stake in Endo International during Q3 for $51,000. First Quadrant LLC CA acquired a new stake in Endo International during Q1 for $36,000. Nisa Investment Advisors LLC increased its position in Endo International by 500.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 18,000 shares of the company valued at $57,000 after purchasing an additional 15,000 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Endo International in Q4 for $68,000. 80.39% of the shares are currently held by institutional investors and hedge funds.

Endo International Company Profile (Get a rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceutical products in the United States and around the world. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren’s disease; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, injectable treatment for moderate to severe cellulite of the buttocks in adult women; PERCOCET to treat moderate to moderately severe pain; TESOPEL an implantable pellet indicated for TRT in pathologies associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch containing lidocaine for pain relief; and products for pain management and urology.

Recommended Stories

Get a Free Copy of Zacks Research Report on Endo International (ENDP)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)



Get news and reviews for Endo International Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Endo International and related companies with MarketBeat.com’s FREE daily newsletter.

Share.

About Author

Comments are closed.